2m 2m 2m 2m 2m 2m - S&P 600$1,709.07
2m
- $54.1BMarket Cap
- 75.13%1-Year Change
- Drug Manufacturers - Specialty & GenericIndustry
TEVA PHARMA IND (TEVA)
Key Performance
More- Earnings Score: 63
- Momentum Score: 52
- True Yield: N/A
- Financial Health Score: 100
Latest Research & News
Global Injectables Market is Anticipated to Surpass USD 1 Trillion Mark by 2034 | DelveInsight
The global injectables market is projected to grow from USD 765 billion in 2025 to USD 1.6 trillion by 2034, with a CAGR of approximately 9%. Growth is driven by rising adoption of biologics, biosimilars, GLP-1 therapies, and advances in drug-delivery technologies like prefilled syringes and auto-injectors. North America leads with 39% market share, while Asia-Pacific represents the fastest-expanding region. Key developments include West Pharmaceutical Services' Dublin expansion and Fresenius Kabi's U.S. manufacturing collaboration.
11/11/2026, 1:00 PM • GlobeNewswire
The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.
11/10/2026, 11:00 AM • GlobeNewswire
The global paracetamol market is projected to grow from USD 12.05 billion in 2026 to USD 15.39 billion by 2032, registering a CAGR of 4.12%. Growth is driven by rising demand for pain and fever management, expanding over-the-counter medicine access, and manufacturing capacity investments. Asia-Pacific is the fastest-growing region, while North America maintains the largest market share at 33.68%. However, generic competition and pricing pressure continue to influence supplier margins.
11/10/2026, 5:00 AM • GlobeNewswire
Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?
Teva Pharmaceuticals is executing a successful turnaround strategy, shifting from generics to higher-margin branded therapies. Its three key drugs (Austedo, Ajovy, Uzedy) grew sales 33% year-over-year to $1.1 billion in Q3, while gross margins improved to 55.5%. The company has paid down $12 billion in debt since 2019 and received investment-grade ratings. However, overall Q3 revenue declined 2% due to generic drug competition, and the company faces headwinds from commoditized generics. Despite recent gains, the stock trades at less than 21x forward earnings.
11/06/2026, 8:48 AM • The Motley Fool
Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?
Teva Pharmaceutical has surged 108% over the past year due to its successful pivot from generic drugs to branded drugs. The company's flagship branded drugs (Ajovy, Austedo, Uzedy) are showing strong growth with year-over-year revenue increases of 40-56%. Analysts project moderate continued gains with potential stock price reaching low-$50s in three years, though a 38% price reduction for Austedo effective January 2027 poses a potential headwind.
10/30/2026, 11:00 AM • The Motley Fool
Where Will Neurocrine Biosciences Be in 5 Years?
Neurocrine Biosciences generated $959 million in Q2 2026 revenue with 39% year-over-year growth. The company's flagship drug Ingrezza continues strong double-digit growth, while newer treatments Crenessity and Vykat XR are expanding rapidly. With late-stage clinical trials for depression and schizophrenia treatments expected in 2027, analysts project the company could reach $6-7 billion in annual revenue by 2031, though success depends on pipeline candidates and managing pricing pressures.
10/25/2026, 6:45 AM • The Motley Fool
The global migraine market is projected to grow at a 6% CAGR through 2036, reaching expansion driven by rising prevalence, improved diagnosis rates, and development of novel therapies beyond CGRP inhibitors. Key emerging treatments include PACAP-targeted therapies, TRPA1 antagonists, and next-generation neuromuscular approaches. The market was valued at USD 8.3 billion in 2025 across seven major markets, with the United States leading.
10/19/2026, 1:00 PM • GlobeNewswire
The global brain health supplements market is projected to grow from USD 12.47 billion in 2025 to USD 35.41 billion by 2035, driven by increasing consumer awareness of cognitive wellness, demand for natural ingredients, and e-commerce expansion. North America leads with 43.1% market share, while memory enhancement remains the top application. Key growth factors include aging populations, younger consumers seeking cognitive support, and clinical validation of natural ingredients like Bacopa monnieri and Ginkgo Biloba.
10/16/2026, 4:57 AM • GlobeNewswire
Teva to Host R&D Day on Wednesday, November 11 in New York City
Teva Pharmaceutical Industries announced it will host an R&D Day on November 11, 2026, in New York to discuss its R&D pipeline and transformation strategy into an innovative biopharma company. The company also announced FDA approval of WELTRUZA™ (olanzapine), the first and only once-monthly subcutaneous injectable olanzapine for adults with schizophrenia.
10/12/2026, 5:45 PM • GlobeNewswire
Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround
Teva Pharmaceutical has surged 110% in the last year, hitting a 52-week high of $40.79 per share, driven by its pivot from generic to branded drugs. The company's innovative portfolio of three branded products is projected to generate $3.7 billion in 2026 revenue, while net debt has decreased from $18.4 billion (end of 2022) to $12.9 billion, earning a credit rating upgrade to investment-grade status. With peak annual sales of $10 billion anticipated from its late-stage pipeline and earnings expected to grow 40.7% between 2026-2027, analysts view the stock as undervalued at 12.9x forward earnings.
09/29/2026, 5:35 AM • The Motley Fool
Teva Releases Q3 2026 Aide Memoire
Teva Pharmaceutical Industries Ltd. announced the availability of its Q3 2026 Aide Memoire document to assist investors ahead of third quarter 2026 results, scheduled for release on November 3, 2026, followed by a conference call at 8:00 a.m. ET. The company is transforming into a leading innovative biopharmaceutical company supported by its generics business.
09/23/2026, 4:45 PM • GlobeNewswire
Teva Pharmaceutical Industries announced it will release its Q3 2026 financial results on November 3, 2026, at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET. The company is executing its Pivot to Growth strategy focused on expanding its innovative and biosimilar medicines pipeline while maintaining its generics business.
09/23/2026, 4:45 PM • GlobeNewswire
Teva released findings from a discrete choice experiment showing that healthcare providers prioritize somnolence risk, long-term efficacy data, and drug-drug interaction profiles when selecting treatments for tardive dyskinesia in patients aged 55+. AUSTEDO (deutetrabenazine) was found to align most closely with these preferred attributes across all patient profiles. Additionally, data from the IMPACT-TD Registry showed that untreated tardive dyskinesia persists in 89-96% of patients over 24 months with no spontaneous resolution, underscoring the need for proactive treatment.
09/18/2026, 4:32 PM • GlobeNewswire
Teva announced real-world data demonstrating that UZEDY (risperidone) extended-release injectable suspension shows superior treatment continuity compared to other long-acting injectables in schizophrenia patients and oral antipsychotics in bipolar I disorder. The data revealed UZEDY reduced emergency room visits and hospitalizations, delivering over $1,000 per patient per month in direct cost savings and 40% lower emergency department visit rates versus paliperidone palmitate once-monthly.
09/18/2026, 4:31 PM • GlobeNewswire
Teva presented post hoc data from the Phase 3 SOLARIS trial for TEV-'749, a once-monthly subcutaneous long-acting injectable olanzapine formulation for schizophrenia treatment. Results showed over 56% of participants achieved stabilization, 21% achieved remission after 6+ months, and only 4% of stabilized patients relapsed. Data also demonstrated feasible switching strategies from oral or short-acting olanzapine formulations while maintaining therapeutic ranges. FDA approval is anticipated in Q4 2026.
09/18/2026, 4:30 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 11/13/2026
Company Profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Key Executives
- Richard Francis
- Eliyahu Sharon Kalif
- Eric A. Hughes
- Christine Fox
- Evan Lippman
Current Ownership Distribution
- Institutions12.2B (55.85%)
- Mutual Funds9.7B (44.12%)
- Insiders5.1M (0.02%)
- Other0 (0.00%)